CN115068536A - Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof - Google Patents

Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof Download PDF

Info

Publication number
CN115068536A
CN115068536A CN202210784533.8A CN202210784533A CN115068536A CN 115068536 A CN115068536 A CN 115068536A CN 202210784533 A CN202210784533 A CN 202210784533A CN 115068536 A CN115068536 A CN 115068536A
Authority
CN
China
Prior art keywords
parts
powder
medicinal
marigold extract
mulberry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210784533.8A
Other languages
Chinese (zh)
Inventor
鄢贵
沈刚
刘姗姗
施后奎
曹冬
郑午
金冶
林勇
胡攀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210784533.8A priority Critical patent/CN115068536A/en
Publication of CN115068536A publication Critical patent/CN115068536A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine-food homologous composition for relieving visual fatigue, which is prepared from the following raw materials in parts by weight: 2-30 parts of medlar, 2-20 parts of mulberry, 2-20 parts of kudzu root, 2-20 parts of chrysanthemum, 2-20 parts of cassia seed, 0.1-5 parts of blueberry powder and 0.001-0.05 part of marigold extract. The medicinal and edible composition prepared based on the traditional Chinese medicine and food theory has high safety, can effectively relieve liver-kidney yin deficiency type asthenopia, protect the eyesight of people, improve the life quality, and has practical popularization and application values.

Description

Medicinal and edible composition for relieving visual fatigue and preparation method and application thereof
Technical Field
The invention belongs to the field of traditional Chinese medicine health care, and particularly relates to a medicine-food homologous composition for relieving visual fatigue and a preparation method and application thereof.
Background
Eye fatigue, also defined as asthenopia, is a common condition in adults and children. Eye fatigue can be caused by a variety of factors, including ocular, psychological and environmental factors. With the popularization of video terminals such as computers and smart phones and the change of life styles, the number of visual fatigue patients increases day by day, and the visual sense and the life quality of the visual fatigue patients are seriously affected. According to the reports in European and Asian countries, the prevalence is 12-26% among children 5-16 years of age. In Chinese college students, the prevalence of asthenopia is 53-57%. Therefore, there is an urgent need to develop an effective strategy to prevent eye fatigue and alleviate the manifestations associated with asthenopia.
Traditional Chinese medicine considers that the cause of the asthenopia is complex, and the asthenopia relates to various aspects such as liver-kidney yin deficiency, qi stagnation and blood stasis, qi-blood deficiency, spleen and stomach weakness and the like, and is stimulated by long-term vision, emotion and the like, wherein the liver-kidney yin deficiency is one of the main common syndrome differentiation and type classification of the asthenopia. In daily life, people already use the mulberry, the medlar, the cassia seed, the chrysanthemum and the like which have the efficacies of nourishing liver and kidney, tonifying qi and strengthening spleen and improving eyesight for eye protection and eyesight preservation and health care, but the mulberry, the medlar, the cassia seed, the chrysanthemum and the like are eaten or drunk daily, lack reasonable and effective compatibility and have poor effect on relieving asthenopia. Patent CN107519338A discloses an external traditional Chinese medicine composition for protecting eyesight, which has 12 medicinal ingredients, and can achieve the effect of relieving asthenopia by being externally applied to the periphery of eye sockets and being matched with a physical therapy instrument for use. Patent CN 112715729A discloses a blueberry lutein ester tablet candy for relieving visual fatigue, which is a result of multifactor action due to the visual fatigue, and the visual fatigue state can not be fundamentally conditioned only by supplementing lutein ester and blueberry powder, so that a good effect of specifically relieving the visual fatigue is achieved.
Disclosure of Invention
In order to solve the problems, the invention provides a medicinal and edible composition for relieving visual fatigue, which is prepared from the following raw materials in parts by weight:
2-30 parts of medlar, 2-20 parts of mulberry, 2-20 parts of kudzu root, 2-20 parts of chrysanthemum, 2-20 parts of cassia seed, 0.1-5 parts of blueberry powder and 0.001-0.05 part of marigold extract.
Further, the traditional Chinese medicine is prepared from the following raw material medicines in parts by weight:
2-25 parts of medlar, 2-15 parts of mulberry, 2-15 parts of kudzu root, 2-15 parts of chrysanthemum, 2-15 parts of cassia seed, 0.4-3 parts of blueberry powder and 0.005-0.04 part of marigold extract.
Furthermore, the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
5-10 parts of medlar, 5-8 parts of mulberry, 4-8 parts of kudzu root, 3-6 parts of chrysanthemum, 3-8 parts of cassia seed, 0.8-2 parts of blueberry powder and 0.01-0.03 part of marigold extract.
Furthermore, the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
7 parts of medlar, 7 parts of mulberry, 5 parts of kudzuvine root, 5 parts of chrysanthemum, 7 parts of cassia seed, 1 part of blueberry powder and 0.03 part of marigold extract;
or: 7 parts of medlar, 5 parts of mulberry, 7 parts of kudzuvine root, 5 parts of chrysanthemum, 7 parts of cassia seed, 1 part of blueberry powder and 0.02 part of marigold extract.
Further, the content of lutein in the marigold extract is more than 8%, and preferably the content of lutein in the marigold extract is 10%.
Furthermore, the oral preparation is prepared by taking extracts of barbary wolfberry fruit, mulberry, kudzuvine root, chrysanthemum, cassia seed, blueberry powder and marigold as active ingredients and adding pharmaceutically acceptable auxiliary materials.
Furthermore, the adjuvants include filler, disintegrating agent, lubricant, suspending agent, binder, sweetener, correctant, antiseptic, and matrix.
Further, the oral preparation is granule, powder, pill or solution.
The invention also provides a preparation method of the medicinal and edible composition, which comprises the following steps:
(1) weighing the raw materials according to the proportion; oven drying fructus Lycii, fructus Mori, radix Puerariae, flos Chrysanthemi and semen Cassiae, and pulverizing;
(2) adding water into the powder obtained in the step (1) for extraction, and concentrating and drying an extracting solution to obtain extracted powder;
(3) and (3) taking the extracted powder obtained in the step (2), adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the blueberry and marigold extract.
Further, the powder in the step (1) is sieved by a 200-mesh sieve with 100 meshes;
and/or, the extraction in the step (2) is decoction extraction; the decoction is carried out twice, and 8-15 times of w/w of water is added for decoction for 50-70 minutes each time;
and/or, the drying is spray drying; the air inlet temperature of the spray drying is 130 ℃, and the air outlet temperature is 60 ℃.
The invention finally provides application of the medicinal and edible composition in preparation of a medicine and/or food for relieving visual fatigue.
Further, the medicine is a medicine for relieving liver-kidney yin deficiency type asthenopia.
Further, the food is a health food for relieving liver-kidney yin deficiency type asthenopia.
The composition of the invention comprises the following components: is dry mature fruit of Lycium barbarum L belonging to Solanaceae, has sweet taste, neutral nature, and effects of nourishing liver and kidney, replenishing vital essence, invigorating kidney, replenishing vital essence, and improving eyesight, and can be used for treating asthenia, soreness of waist and knees, giddiness, tinnitus, sexual impotence, nocturnal emission, internal heat, diabetes, blood deficiency, sallow complexion, and blurred vision. Is rich in polysaccharide, flavone, fat-soluble carotenoid, etc. Carotenoid in fructus Lycii, i.e. zeaxanthin, xanthophyll, beta-carotene, and various bioactive components such as LBP, TFLB, betaine, etc., has synergistic effect in protecting eyesight.
Cassia seed: is dried mature seed of Cassia obtusifolia L. or Cassia tora L. of Leguminosae. It is sweet, bitter, salty and slightly cold in nature, enters liver and large intestine channels, and has the functions of clearing liver and improving vision, and relaxing bowel. Contains anthraquinone, naphtho-pyrone, fatty acid, non-saponified matter, polysaccharide, amino acid, inorganic element, etc. and has the functions of improving eyesight, lowering blood pressure, reducing blood fat, protecting liver, etc.
Kudzu root: is dried root of Ohwi of Pueraria lobata (Willd.) Ohwi of Leguminosae. Sweet, pungent and cool in nature; it enters spleen, stomach and lung meridians. Expelling pathogenic factors from muscles and skin, relieving fever, promoting salivation, quenching thirst, promoting eruption, invigorating yang, relieving diarrhea, dredging meridian passage, and relieving alcoholism. Mainly contains flavonoid, triterpene, coumarin, organic acid, etc. The puerarin has pharmacological actions of protecting liver, resisting tumor, protecting nerve, protecting heart, improving insulin resistance, resisting inflammation, resisting oxidation, etc., and has obvious curative effect on asthenopia.
Chrysanthemum: is a dried capitula of Compositae plant Chrysanthemum morifolium Ramat. Chrysanthemum is sweet and bitter, has slight cold, enters lung and liver meridians, has the effects of calming liver, improving eyesight, clearing heat and detoxicating, and can be used for treating wind-heat type common cold, blurred vision, conjunctival congestion, swelling and pain, sore and carbuncle swelling and toxin. Mainly contains phenolic acid compounds, flavonoid compounds, volatile oil and other chemical components, and has pharmacological activities of diminishing inflammation, resisting bacteria, lowering blood pressure, lowering blood fat and the like.
Mulberry: is dried fruit cluster of Morus alba L. Has sweet and sour taste and cold property, and has effects of nourishing liver and invigorating kidney, nourishing blood and promoting fluid production, nourishing fluid and calming endogenous wind, and loosening bowel to relieve constipation, and can be used for treating liver and kidney yin deficiency, dim eyesight and tinnitus, body fluid deficiency, blood deficiency constipation, internal heat diabetes, lymphoid tuberculosis, joint difficulty, neurasthenia, etc. Mainly contains chemical components such as polysaccharide, flavone and the like, and has pharmacological actions such as immunoregulation, antioxidation, blood sugar reduction, lipid reduction, cancer resistance, mutation resistance and the like.
Marigold: it is rich in lutein ester, can be naturally decomposed and converted into lutein in human body, and has effects of protecting vision, relieving asthenopia, preventing senile macular region pathological change, cataract, promoting health and other antiaging effects.
Blueberry: is rich in anthocyanin, and has effects of relieving asthenopia, promoting rhodopsin regeneration in retina cell, preventing myopia, and improving vision.
The compatibility of the medicines is precise and appropriate, and the effect of treating the liver-kidney yin deficiency type asthenopia is obvious on the basis of the treatment principles of treating the symptoms and root causes slowly and quickly, preventing and treating early change, strengthening body resistance and eliminating evil and under the guidance of treatment methods of nourishing liver and kidney and benefiting essence and improving eyesight. The test proves that: the medicinal and edible composition prepared based on the traditional Chinese medicine and food theory has high safety, can effectively relieve liver-kidney yin deficiency type asthenopia, protect the eyesight of people, improve the life quality, and has practical popularization and application values.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
The raw materials and equipment used in the embodiment of the present invention are known products and obtained by purchasing commercially available products.
Example 1 composition for relieving asthenopia according to the present invention
The formula is as follows: 5g of medlar, 5g of mulberry, 7g of cassia seed, 0.6g of blueberry powder and 0.02g of marigold extract (the content of lutein is 10%).
The preparation method comprises the following steps:
weighing fructus Lycii, Mori fructus, and semen Cassiae, oven drying at 60 deg.C for 30min, pulverizing, adding the medicinal powder into an extraction tank, adding 12 times of water, boiling, and extracting for 1.5 hr. Filtering to obtain extractive solution, decocting the residue once again, adding 12 times of water, boiling for 1.5 hr, filtering, and mixing filtrates; concentrating under reduced pressure until the relative density of the extract is 1: 1.2, spray drying to obtain extract powder, adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the composition.
Example 2 asthenopia-relieving composition of the invention
The formula is as follows: 5g of medlar, 5g of mulberry, 7g of kudzu root, 7g of cassia seed, 0.6g of blueberry powder and 0.02g of marigold extract (the content of lutein is 10%).
The preparation method comprises the following steps:
weighing fructus Lycii, Mori fructus, radix Puerariae and semen Cassiae, oven drying at 60 deg.C for 30min, pulverizing, adding the medicinal powder into an extraction tank, adding 12 times of water, boiling and extracting for 1.5 hr. Filtering to obtain extractive solution, decocting the residue once again, adding 12 times of water, boiling for 1.5 hr, filtering, and mixing filtrates; concentrating under reduced pressure until the relative density of the extract is 1: 1.2, spray drying to obtain extract powder, adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the composition.
Example 3 asthenopia-relieving composition of the invention
The formula is as follows: 5g of medlar, 7g of mulberry, 7g of kudzuvine root, 7g of chrysanthemum, 5g of cassia seed, 0.8g of blueberry powder and 0.03g of marigold extract (the content of lutein is 10%).
The preparation method comprises the following steps:
weighing fructus Lycii, Mori fructus, radix Puerariae, flos Chrysanthemi and semen Cassiae, oven drying at 60 deg.C for 30min, pulverizing, adding the medicinal powder into an extraction tank, adding 10 times of water, and boiling for 1 hr. Filtering to obtain extractive solution, decocting the residue once again, adding water 8 times the mass of the Chinese medicinal materials, boiling and extracting for 1 hr, filtering, and mixing filtrates; concentrating under reduced pressure until the relative density of the extract is 1: 1.2, spray drying to obtain extract powder, adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the composition.
Example 4 asthenopia-relieving composition of the invention
The formula is as follows: 7g of medlar, 5g of mulberry, 7g of kudzuvine root, 5g of chrysanthemum, 7g of cassia seed, 1g of blueberry powder and 0.02g of marigold extract (the content of lutein is 10%).
Preparation method
Weighing fructus Lycii, Mori fructus, radix Puerariae, flos Chrysanthemi and semen Cassiae, oven drying at 60 deg.C for 30min, pulverizing, adding the medicinal powder into an extraction tank, adding 12 times of water, and boiling for 1 hr. Filtering to obtain extractive solution, decocting the residue once again, adding 12 times of water, boiling and extracting for 1 hr, filtering, and mixing filtrates; concentrating under reduced pressure until the relative density of the extract is 1: 1.2, spray drying to obtain extract powder, adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the composition.
Example 5 asthenopia-relieving composition of the invention
The formula is as follows: 7g of medlar, 7g of mulberry, 5g of kudzuvine root, 5g of chrysanthemum, 7g of cassia seed, 1g of blueberry powder and 0.03g of marigold extract (the content of lutein is 10%).
The preparation method comprises the following steps:
weighing fructus Lycii, Mori fructus, radix Puerariae, flos Chrysanthemi and semen Cassiae, oven drying at 60 deg.C for 30min, pulverizing, adding the medicinal powder into an extraction tank, adding 12 times of water, and boiling for 1 hr. Filtering to obtain extractive solution, decocting the residue once again, adding 12 times of water, boiling and extracting for 1 hr, filtering, and mixing filtrates; concentrating under reduced pressure until the relative density of the extract is 1: 1.2, spray drying to obtain extract powder, adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the composition.
The advantageous effects of the present invention are described below by way of test examples.
The traditional Chinese medicine considers that the asthenopia is a recoverable chronic consumptive syndrome, and mainly comprises 3 traditional Chinese medicine syndromes of liver-kidney yin deficiency, liver depression and qi stagnation and qi and blood deficiency, wherein the liver-kidney yin deficiency is mainly used, the liver opens into eyes, the kidney is mainly used for the eyes, and the B and C are homologous. If the eyes are failing to nourish the eyes due to yin deficiency of liver and kidney, the eyes will be dry and dry, and the vision will be blurred.
Test example 1 efficacy test for relieving asthenopia
1.1. Drugs and agents
Cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), Corticosterone (CORT), estradiol (E2), testosterone (T) enzyme immunoassay kit, Malondialdehyde (MDA) and total superoxide dismutase (SOD) test kit
1.2. Laboratory animal
SPF grade (Sprague Dawley, SD) rats, male, 6-7 weeks old, 160-200 g in weight. Feeding conditions are as follows: the temperature is 22-26 ℃, and the relative humidity is 60% -70%.
1.3. Test drug and treatment method
Extracts of the compositions prepared in examples 1, 2, 3, 4, and 5 without excipients; qijudihuang Wan (pill of Qi Ju and Di Huang).
2. Experimental grouping and experimental methods
SD rats are selected and randomly divided into 8 groups, namely a blank group, a model group, a positive control Qijudihuang pill group and a composition group of examples 1, 2, 3, 4 and 5. Beginning on the 1 st day of the experiment, the modeling and the administration of the rats are synchronously carried out, namely, the composition of the examples 1, 2, 3, 4 and 5 is intragastrically administered to the rats in a group (3g/kg) in the morning, the Qiju Dihuang pills are intragastrically administered to a positive control group (3g/kg), and the distilled water with the same amount is intragastrically administered to the rats in a blank group and a model group every day; except for the blank group, the rats in other groups were gavaged with levothyroxine sodium tablet solution 90 μ g/kg daily in the afternoon, the administration volume was 0.01mL/g, and subjected to tail-clamping emotional stimulation, and the tail was clamped with a clip (about 3cm from the tip of the tail) for 5min, 1 time daily for 14 days continuously. After the completion of gavage on day 14, the rat eyeballs were irradiated with a 15000Lux blue light for 3 h. On day 15, blood was taken from the abdominal main vein and rat eyeballs were homogenized.
3. Results of the experiment
1. Rat ethology and body weight observation
1.1 compared with the blank group, the rats in the model group have symptoms of liver and kidney yin deficiency, such as thin body, drinking water, reduced ingestion, yellowish hair, lack of luster, restlessness, dry stool, yellow urine, and the like. The positive control and examples were improved over the model group.
1.2 Effect on rat body weight on days 7 and 14, rats in each group had significantly reduced body weight mass compared to the blank group: ( ** P<0.01). The body weight of the rats in the positive control group and each of the examples was increased as compared with that in the model group ( △△ P<0.01， △ P<0.05). See table 1 for details.
TABLE 1 comparison of body weights of rats in each group at different time points: (
Figure BDA0003731427480000061
n＝6,g)
Figure BDA0003731427480000062
Note: comparison with blank group<0.01, comparing with the model group, △△ P<0.01， △ P<0.05。
2. serum-related index detection
Cyclic nucleotide (cAMP, cGMP), sex hormone (E2, T) and oxidation factor (MDA, SOD) levels in rat serum were determined according to the cassette protocols.
The experimental results in tables 2-3 show that the model group cAMP/cGMP and E2/T are significantly increased ( * P<0.05) to prompt the successful preparation of the model for the experimental kidney yin deficiency syndrome. The positive control group and examples 2-5 all had different degrees of inhibition or regulation of the above index changes in the model rats, and the effect of nourishing liver and kidney was achieved.
The experimental results in table 4 show that the detection results of the rat serum oxidation factor level are consistent with the related literature reports, i.e. the asthenopia degree is positively correlated with the accumulation degree of free radicals in vivo, which shows that the serum MDA content is increased and the SOD content is reduced. The oxidation index level of the model animal is improved by the positive control group, the examples 4 and 5, the visual fatigue relieving effect is achieved to a certain extent, and the antioxidant effect of the 5 groups of the implementation case is optimal.
TABLE 2 comparison of cAMP, cGMP, cAMP/cGMP levels in the serum of rats in each group: (
Figure BDA0003731427480000071
n＝6,g)
Figure BDA0003731427480000072
Note: in comparison with the blank set, the results, * P<0.05; in comparison with the set of models, △△ P＜0.01， △ P＜0.05。
TABLE 3 groups of rats E 2 、T、E 2 (iv) T comparison
Figure BDA0003731427480000073
n＝6,g)
Figure BDA0003731427480000074
Figure BDA0003731427480000081
Note: comparison with blank group<0.05; in comparison with the set of models, △△ P＜0.01， △ P＜0.05。
TABLE 4 comparison of serum oxidation levels in rats of various groups: (
Figure BDA0003731427480000082
n＝6)
Figure BDA0003731427480000083
Note: comparison with blank group<0.01; in comparison with the set of models, △△ P＜0.01， △ P＜0.05。
3. eyeball tissue-related index detection
Cyclic nucleotide (cAMP, cGMP) levels in rat eye homogenates were determined according to the respective cassette protocol.
Cyclic nucleotides are an important bioactive substance, widely exist in human cells, and consist of cAMP and cGMP. The research shows that the ciliary muscle spasm can be contracted after the eyesight or the long-term vision and the like, the cAMP content in the tissues is reduced, and the cGMP content is increased. The experimental results show that the cAMP content in the groups 4 and 5 is obviously increased ( △△ P＜0.01， △ P is less than 0.05), and the cGMP content of the 5 groups of the embodiment cases is obviously reduced ( △ P＜0.05)。
TABLE 5 comparison of the cAMP and cGMP content in the eyeball of each rat group: (
Figure BDA0003731427480000091
n＝6,g)
Figure BDA0003731427480000092
Note: in comparison with the blank set, the results, ** P<0.01; in comparison with the set of models, △△ P＜0.01， △ P＜0.05。
and (4) conclusion: the invention adopts rat gavage levothyroxine sodium combined with tailing emotion to stimulate superimposed photodamage to establish a liver-kidney yin deficiency compound asthenopia rat model, aiming at the imbalance of multiple indexes of liver-kidney yin deficiency syndrome model animals, the control group and the implementation cases 2, 3, 4 and 5 of the pill of Chinese wolfberry-rehmanniae have improvement effects, including weight increase, AMP/cGMP and E2/T level reduction, oxidation product MDA reduction and SOD content increase, the liver-kidney yin deficiency state is relieved through comprehensive effect, and the liver-kidney nourishing effect is exerted, so that asthenopia is relieved, wherein the implementation case 5 has the most obvious antioxidation effect, the implementation cases 4 and 5 can adjust cAMP content in rat eyeball tissues, and the implementation case 5 can reduce cGMP content and prompt that the contraction effect of ciliary muscle spasm caused by overuse, long-term vision and the like is relieved. In conclusion, embodiment 5 has the best effect, and plays a certain role in relieving asthenopia.
In conclusion, the medicinal and edible composition prepared based on the traditional Chinese medicine and food theory has high safety, can effectively relieve liver-kidney yin deficiency type asthenopia, protects the eyesight of people, improves the life quality, and has practical popularization and application values.

Claims (10)

1. A medicine-food homologous composition for relieving visual fatigue is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
2-30 parts of medlar, 2-20 parts of mulberry, 2-20 parts of kudzu root, 2-20 parts of chrysanthemum, 2-20 parts of cassia seed, 0.1-5 parts of blueberry powder and 0.001-0.05 part of marigold extract.
2. The medicinal and edible composition as claimed in claim 1, wherein: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
5-10 parts of medlar, 5-8 parts of mulberry, 4-8 parts of kudzu root, 3-6 parts of chrysanthemum, 3-8 parts of cassia seed, 0.8-2 parts of blueberry powder and 0.01-0.03 part of marigold extract.
3. The medicinal and edible composition as claimed in claim 2, wherein the composition comprises: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
7 parts of medlar, 7 parts of mulberry, 5 parts of kudzuvine root, 5 parts of chrysanthemum, 7 parts of cassia seed, 1 part of blueberry powder and 0.03 part of marigold extract;
or: 7 parts of medlar, 5 parts of mulberry, 7 parts of kudzuvine root, 5 parts of chrysanthemum, 7 parts of cassia seed, 1 part of blueberry powder and 0.02 part of marigold extract.
4. The medicinal and edible composition as claimed in any one of claims 1-3, which is characterized in that: the content of lutein in the marigold extract is more than 8%, and the content of lutein in the marigold extract is preferably 10%.
5. The medicinal and edible composition as claimed in claim 1, wherein: the oral preparation is prepared by taking extracts of barbary wolfberry fruit, mulberry, kudzuvine root, chrysanthemum, cassia seed, blueberry powder and marigold as active ingredients and adding pharmaceutically acceptable auxiliary materials; the oral preparation is granules, powder, pills or solution.
6. The preparation method of the medicinal and edible composition as claimed in any one of claims 1-5, characterized by comprising the following steps: the method comprises the following steps:
(1) weighing the raw materials according to the proportion; oven drying fructus Lycii, fructus Mori, radix Puerariae, flos Chrysanthemi and semen Cassiae, and pulverizing;
(2) adding water into the powder obtained in the step (1) for extraction, and concentrating and drying an extracting solution to obtain extracted powder;
(3) and (3) taking the extracted powder obtained in the step (2), adding blueberry powder, marigold extract and pharmaceutically acceptable auxiliary materials, and uniformly mixing to obtain the blueberry and marigold extract.
7. The method according to claim 6, wherein the powder of step (1) is sieved with 100-200 mesh sieve;
and/or, the extraction in the step (2) is decoction extraction; the decoction extraction is carried out twice, and 8-15 times of w/w of water is added for decoction for 50-70 minutes each time;
and/or, the drying is spray drying; the air inlet temperature of the spray drying is 130 ℃, and the air outlet temperature is 60 ℃.
8. Use of the medicinal and edible composition as defined in any one of claims 1-5 in preparation of medicaments and/or foods for relieving visual fatigue.
9. Use according to claim 7, characterized in that: the medicine is used for relieving liver-kidney yin deficiency type asthenopia.
10. Use according to claim 7, characterized in that: the food is a health food for relieving asthenopia due to deficiency of liver-yin and kidney-yin.
CN202210784533.8A 2022-07-05 2022-07-05 Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof Pending CN115068536A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210784533.8A CN115068536A (en) 2022-07-05 2022-07-05 Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210784533.8A CN115068536A (en) 2022-07-05 2022-07-05 Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN115068536A true CN115068536A (en) 2022-09-20

Family

ID=83257682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210784533.8A Pending CN115068536A (en) 2022-07-05 2022-07-05 Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN115068536A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102894435A (en) * 2011-07-25 2013-01-30 江西食方食坊中药食品有限公司 Mulberry-medlar leaf beverage with function of asthenopia relieving, and preparation method thereof
CN110664904A (en) * 2019-10-24 2020-01-10 武汉有明汉方医药科技有限责任公司 Preparation method of traditional Chinese medicine health food for relieving visual fatigue
CN113287698A (en) * 2021-04-16 2021-08-24 上海信仁医药研究所 Formula and preparation method of eye-protecting beverage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102894435A (en) * 2011-07-25 2013-01-30 江西食方食坊中药食品有限公司 Mulberry-medlar leaf beverage with function of asthenopia relieving, and preparation method thereof
CN110664904A (en) * 2019-10-24 2020-01-10 武汉有明汉方医药科技有限责任公司 Preparation method of traditional Chinese medicine health food for relieving visual fatigue
CN113287698A (en) * 2021-04-16 2021-08-24 上海信仁医药研究所 Formula and preparation method of eye-protecting beverage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕燕等: "四联疗法治疗青少年轻度近视569例临床观察", 亚太传统医药 *

Similar Documents

Publication Publication Date Title
CN110354204B (en) Composition with eyesight improving effect and preparation and application methods thereof
CN105368669A (en) Raw materials for health care wine capable of resisting fatigue and improving immunity and health care wine preparation method
CN104740541B (en) A kind of protecting liver and detoxication restores the Chinese medicine powder for health care of liver function
CN108434256A (en) A kind of removing toxic substances row&#39;s fat that nourishes the liver to improve visual acuity restores the Chinese medicine preparation of liver metabolism function
CN106562413A (en) Oral thick paste for immunity enhancement and preparation method thereof
CN103689152B (en) Herbal tea for tonifying kidney and removing heat from liver and preparation method thereof
CN102114218B (en) Traditional Chinese medicine for tonifying kidney, strengthening yang and resisting fatigue and preparation method thereof
CN103301413A (en) Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia
KR101826737B1 (en) A composition containing herbs extract, and manufacturing method of the same
CN104958445A (en) Chastetree fruit oral liquid for preventing wind-heat upward attacking and swelling and pain of eyes, and preparation method of chastetree fruit oral liquid
CN101301427B (en) Medicament composition and preparation and application thereof
CN104971304A (en) Xerophthalmia treatment medicine
CN107158299B (en) Composition with function of enhancing learning memory and preparation method thereof
CN105560891A (en) Traditional Chinese medicine eye drops containing borneol and preparation method thereof
CN107441429B (en) Anti-alcohol composition and preparation method thereof
CN106177166A (en) A kind of compositions with function of physical fatigue alleviation and preparation method thereof
CN112007122B (en) Traditional Chinese medicine composition for tonifying primordial qi, calming heart, tonifying spleen, eliminating dampness and regulating immunity of organism and preparation method thereof
CN115068536A (en) Medicine and food homologous composition for relieving visual fatigue as well as preparation method and application thereof
CN113499425A (en) Composition for treating viral influenza and preparation method thereof
CN113826882A (en) Dietary nutrition supplement for preventing and treating diabetes and preparation process thereof
CN110882362A (en) Traditional Chinese medicine food therapy product for conditioning diabetes and preparation method thereof
CN111084878A (en) Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof
CN110179966A (en) The preparation method and applications of traditional Chinese medicine composition for relieving asthenopia
CN114796358B (en) Traditional Chinese medicine composition for relieving asthenopia and preparation method and application thereof
CN111388604B (en) Traditional Chinese medicine composition for treating migraine and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination